Page 16 - Pharma Sector

Sun Pharma to acquire US based Checkpoint Therapeutics for $355 million

The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations

US tariffs to hit pharma sector, while auto industry impact remains minimal

Enhanced tariffs on pharma imports in the US can severely impact Indian drug manufacturers as it would lead to higher production costs, making shipments less competitive against products from other countries. Smaller drug firms operating on thin margins can face severe pressure potentially forcing consolidation or closure. The automobile sector, on the other hand, is expected to have a very minimal impact owing to the US being a small export market. Terming India as a very high tariff nation, US President Donald Trump has said that reciprocal tariffs on countries that impose levies on American goods will kick in on April 2. India currently levies around 10 per cent import duty on American drugs, while the US doesn't charge any import duty on Indian drugs. Shardul Amarchand Mangaldas & Co Partner Arvind Sharma said as of recent history, the US has been a net importer of pharmaceutical products to meet its domestic demand. "In the event the US decides to impose substantial tariffs

Biocon Biologics, Civica partner to expand Insulin Aspart access in the US

Biocon Biologics' own Insulin Aspart drug product for the US is currently under review by the US Food and Drug Administration (FDA)

Piramal Enterprises hit with nearly $172 million tax bill for pharma deal

A tax office in the state of Maharashtra has asked the financial services company to pay 18% Goods and Services Tax (GST) on the deal, the latter said in the filing

Tariffs should not determine how Indian drugmakers operate: Cipla CEO

India, often dubbed the "pharmacy of the world", is among the top exporters to the U.S., especially for cheaper versions of popular drugs

From automobile to FMCG sector: Earnings growth engine in slow lane

IT services firms, while reporting modest single-digit revenue growth, saw improved margins. Here is the top 10 sectors' earnings scorecard

Indian pharma sector's regulatory violation instances fell 11% in '24

In 2014, the share of OAI status globally stood at 6 per cent which has now more than doubled standing at 14 per cent

Misleading medical ads: SC move must lead to stronger regulations

Enabling citizens to complain against medical ad is proactive

Mankind Pharma sets sights on Novo Nordisk's anti-obesity drug Semaglutide

The firm is focusing on specialty chronic therapies like immunotherapy, antibody-drug conjugates, and gene therapy drugs, besides peptides like Glucagon-like peptide-1 (GLP-1)

Indian drugmakers to stay competitive despite US tariff plans: Dr Reddy's

The industry is still waiting for more clarity on any tariffs before taking any action, Prasad said on the sidelines of the BioAsia conference in the Southern Indian state of Telangana

Biocon share price up 2% as arm launches Yesintek in US; check details here

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available to patients in US

Pharma sector can deliver 100 new drugs by 2047: Zydus chairman

Indian pharma industry is capable of delivering 100 new drugs by 2047 for global markets backed by enhanced research and development efforts, Zydus Lifesciences Chairman Pankaj R Patel said on Friday. Speaking at an event here, he stressed the need for innovation, capability building, and a focus on societal benefit. "I believe India can deliver 100 new chemical entities or new drugs to the world by 2047 and off course, it will require effort," Patel said while speaking at the SOUL leadership conclave 2025. He termed it a myth that drug discovery requires a billion dollars while emphasising that it is possible with the right approach. Patel also asserted that the people working in an organisation are the most valuable resource and pitched for an environment where people love to work. He also emphasised the evolving nature of leadership, highlighting the importance of humility, vision, and a global perspective. Patel also shared experiences, including the Prime Minister's proactiv

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

NPPA directs pharma firms to update MRP after Budget 2025 duty exemptions

The National Pharmaceutical Pricing Authority directs pharma firms to revise the MRP of medicines following customs duty exemptions in Union Budget 2025, ensuring consumers benefit from lower prices

Aurobindo Pharma to begin supplies to Europe from China plant in April

Aurobindo Pharma will commence supplies to Europe from its China facility from April onwards, according to Chief Financial Officer Santhanam Subramanian. The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up the production. "The China plant will start billing sometime in the month of April, mainly to the European markets," Subramanian told analysts in a call. The company has received European regulatory approvals and can initiate product supply to the market, he added. "We are in the process of getting it (in China) and after that there may be an inspection for the US (market) also," Subramanian said. The company expects good traction coming out of the China plant over the next 2-3 years, he noted. When asked about revenue projections, Subramanian stated: "This being the first year, we may not like to, but certainly I see a significant revenue coming up in two to three years' time." On a query regarding the ..

Nifty Pharma index slips 3%; Natco, Glenmark, Lupin, Laurus down up to 10%

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.

PI Industries hits 52-week low; down 11% in one week on poor Q3 earnings

PI Industries' steady Q3FY25 performance, cautious near-term outlook, and portfolio challenges are likely to affect the business dynamics in FY26 and FY27, according to analysts.

Analysts bullish on Lupin after Q3; share pops 6%; Goldman Sachs ups target

Domestic, as well as global brokerages are optimistic about Lupin's future, citing strong earnings visibility and a promising product pipeline

Chemists' association seeks meeting with NPPA over price display issue

The NPPA, in an office memorandum (OM) dated February 4, had directed medicine retailers as well as online pharmacies to "conspicuously" display current drug price list

Medicine retailers, e-pharmacies asked to display DPCO's drug price list

National pharma pricing regulator says list has to be put up 'conspicuously'